Reuters logo
BRIEF-Prometic's PBI-4050 significantly reduces liver fibrosis in patients with alström syndrome
October 12, 2016 / 10:16 AM / a year ago

BRIEF-Prometic's PBI-4050 significantly reduces liver fibrosis in patients with alström syndrome

Oct 12 (Reuters) - Prometic Life Sciences Inc :

* Prometic’s PBI-4050 significantly reduces liver fibrosis in patients with alström syndrome

* Prometic Life Sciences-significant reduction of established liver fibrosis demonstrated in all patients that completed 12 weeks of PBI-4050 treatment

* Prometic Life Sciences Inc - liver enzymes reduced to within normal ranges in all patients that completed 12 weeks of PBI-4050 treatment

* Prometic Life Sciences Inc - alström syndrome clinical program to be expanded to include further sites throughout europe and north america

* Prometic Life Sciences-drug safety monitoring board recommended patient enrolment should continue in co’s ongoing alström syndrome phase 2 clinical trial Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below